Sun Xiu-Li, Wang Hai-Bo, Wang Zhi-Qi, Cao Ting-Ting, Yang Xin, Han Jing-Song, Wu Yang-Feng, Reilly Kathleen H, Wang Jian-Liu
Department of Obstetrics and Gynecology, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng Dist, Beijing, 100044, China.
Peking University Clinical Research Institute, Xueyuan Rd 38#, Haidian Dist, Beijing, 100191, China.
BMC Cancer. 2017 Jun 15;17(1):416. doi: 10.1186/s12885-017-3387-1.
Class III radical hysterectomy (RH III)_plus pelvic lymphadenectomy is the standard surgery for early stage cervical cancer (CC) patients, the 5 year survival rate is about 90%, but pelvic floor disorders especially bladder dysfunction are common due to damaged vessels and nerve fibers following surgery. Transcutaneous electrical stimulation (TENS) treatment has been used to treat bladder disorders for many years, but its effect on cervical cancer patients, the best treatment time point and stimulated protocol, had never been assessed. The aim of this study is to investigate the efficacy of TENS treatment on lower urinary tract symptoms (LUTS) after RH III in CC patients.
METHODS/DESIGN: The study will be conducted as a clinical, multicentre, randomised controlled trial with balanced randomisation (1:1). The planned sample size is 208 participants (at 1:1 ratio, 104 subjects in each group). At 5-7 days after RH III, patients are screened according to operative and pathological findings. Enrolled participants are randomised into an intervention group (TENS plus conventional clinical care) or control group (conventional clinical care), with stratification by menopausal status (menopause vs. non-menopause) and surgical modality (laparoscopic RH or abdominal RH). Participants in both groups will be followed up at 14 days, 21 days, 28 days, 3 months, 6 months, 12 months, 18 months and 24 months after surgery. The primary endpoint is improvement rate of urination function which is defined as recovery (residual urine ≤50 ml) or improvement (residual urine 50-100 ml). Secondary endpoints include urodynamic parameter, urinary incontinence, anorectal function, pelvic function, quality of life (QOL), disease-free survival and adverse events. Primary endpoint analyses will be carried out by Cochran-Mantel-Haenszel tests taking into center effect.
To our knowledge this is the first trial to investigate the effect of TENS treatment on bladder function recovery after RH III among CC patients. This study will provide new information on TENS efficacy for bladder function recovery. Once confirmed, it may help to provide a new, non-invisive treatment for those postoperative CC patients with poor pelvic function, which would help improve their quality of life.
The study is registered to Clinical Trials.gov ( NCT02492542 ) on June 25, 2015.
Ⅲ类根治性子宫切除术(RH III)加盆腔淋巴结清扫术是早期宫颈癌(CC)患者的标准手术,5年生存率约为90%,但由于术后血管和神经纤维受损,盆底功能障碍尤其是膀胱功能障碍很常见。经皮电刺激(TENS)治疗已用于治疗膀胱疾病多年,但其对宫颈癌患者的疗效、最佳治疗时间点和刺激方案从未得到评估。本研究的目的是探讨TENS治疗对CC患者RH III术后下尿路症状(LUTS)的疗效。
方法/设计:本研究将作为一项临床、多中心、随机对照试验进行,采用均衡随机化(1:1)。计划样本量为208名参与者(按1:1比例,每组104名受试者)。在RH III术后5-7天,根据手术和病理结果对患者进行筛查。纳入的参与者被随机分为干预组(TENS加常规临床护理)或对照组(常规临床护理),按绝经状态(绝经与未绝经)和手术方式(腹腔镜RH或腹部RH)分层。两组参与者将在术后14天、21天、28天、3个月、6个月、12个月、18个月和24个月进行随访。主要终点是排尿功能改善率,定义为恢复(残余尿量≤50ml)或改善(残余尿量50-100ml)。次要终点包括尿动力学参数、尿失禁、肛门直肠功能、盆腔功能、生活质量(QOL)、无病生存期和不良事件。主要终点分析将采用考虑中心效应的Cochran-Mantel-Haenszel检验进行。
据我们所知,这是第一项研究TENS治疗对CC患者RH III术后膀胱功能恢复影响的试验。本研究将为TENS对膀胱功能恢复的疗效提供新信息。一旦得到证实,它可能有助于为那些盆腔功能较差的CC术后患者提供一种新的非侵入性治疗方法,这将有助于提高他们的生活质量。
该研究于2015年6月25日在ClinicalTrials.gov注册(NCT02492542)。